CRU 2025: Interventional glaucoma as a proactive approach to glaucoma management

News
Video

Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.

Deborah Ristvedt, DO, from Vance Thompson Vision discusses the significant evolution of glaucoma treatment over the past decade. The presentation focuses on moving beyond traditional eye drop treatments to more proactive and patient-friendly interventional approaches. The key shift in glaucoma care is transitioning from a reactive to a preventative model. Ristvedt emphasizes that drops are no longer the only or best solution, highlighting several misconceptions in current glaucoma treatment. While medications can be effective, patient compliance and side effects remain significant challenges. Modern glaucoma management now includes multiple innovative techniques, including selective laser trabeculoplasty (SLT) for consistent 24/7 pressure control, procedural pharmaceuticals that directly target eye pressure, minimally invasive glaucoma surgeries (MIGS) focusing on the trabecular meshwork, and novel devices addressing aqueous fluid production and flow.

The ultimate goals are comprehensive 24/7 pressure control and preventing vision loss. Ristvedt notes that currently, 13% of patients still risk losing vision in one eye, making early intervention crucial. A critical aspect of improved glaucoma care is patient education and early detection. Ristvedt stresses the importance of collaboration between ophthalmology and optometry to help patients understand glaucoma and overcome fears about treatment. Emerging technologies like ocular perfusion goggles for treating normal tension glaucoma represent exciting advancements. The focus is on individualizing care, reducing patient burden, and intervening earlier in the disease progression. The future of glaucoma treatment looks promising, with an increasing number of techniques and devices that allow more personalized, less invasive, and more effective management strategies. By educating patients and implementing these advanced treatments, healthcare professionals can help patients maintain long-term vision and quality of life.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD, and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
Dr Ashley Tucker Wallace discusses the intersection of pediatric dry eye and myopia control
Karen R. Hoffman, OD, speaks on her AOA 2025 poster, which details a case series on fitting patients with irregular cornea and astigmatism with Zenlens (Bausch + Lomb)
Connecting with colleagues, taking courses, and gathering insight for Optometry Times
Ashley Mills, CEO of The Vision Council, gives insight into the decision to move to a single annual meeting and shares the vision for the meeting going forward.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
© 2025 MJH Life Sciences

All rights reserved.